Dr.Reddy’s gearing up with Covid portfolio: Deepak Sapra, CEO of API & Services, speaks to India Today
Dr Reddy’s Laboratories is strengthening its efforts to bring both curative and preventive products (drugs and vaccines) to fight Covid-19. With the launch of Redyx (Remdesivir) and Avigan (Favipiravir), Dr.Reddy’s has reaffirmed its commitment to bring critical medicines for patients suffering from Covid-19.
In addition to the medicines, Dr.Reddy’s has also received 1.5 lakh doses of Sputnik V vaccine from Russia on May 1, 2021 and is currently in the process of rolling out the vaccine in India. The company expects a steady ramp up over May and June and plan to vaccinate 125 million people in the next 8-12 months across the country. Dr Reddy’s is also working with RDIF to launch in a few other markets, particularly in emerging markets.
Deepak Sapra, CEO - API and Services, spoke to India today about Sputnik V vaccine’s clearance, soft launch, production in India, pricing and the road ahead for Sputnik V light.
Click here to view Deepak Sapra exclusive interview with India Today.
Please fill in the following form and we'll get back to you shortly.